Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: Results from the Croatian PROMO Study

Clinical Rheumatology

Volumn 28, Issue 3, 2009, Pages 321-326

  Kastelan, Darko ^a   Lozo, Petar ^b   Stamenkovic, Doris ^c   Miskic, Blazenka ^d   Vlak, Tonko ^e   Kolak, Zeljka ^f   Milas Ahic, Jasminka ^g   Altabas, Velimir ^h   Crncevic Orlic, Zeljka ^c   Korsic, Mirko ^a  

^a KBC Zagreb   (Croatia)

^b Outpatient Clinic for Gynaecology Lozo   (Croatia)

^c KBC RIJEKA   (Croatia)

^d DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

^e UNIVERSITY HOSPITAL SPLIT   (Croatia)

^f General Hospital Vinkovci   (Croatia)

^g UNIVERSITY HOSPITAL OSIJEK   (Croatia)

^h SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Adherence; Ibandronate; Osteoporosis; Preference; Weekly bisphosphonates

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; RISEDRONIC ACID;

AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; CROATIA; DOSAGE SCHEDULE COMPARISON; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PATIENT ATTITUDE; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY OF LIFE; UNSPECIFIED SIDE EFFECT;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT SATISFACTION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; TIME FACTORS;

EID: 59749093247     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-008-1039-1     Document Type: Article

References (23)

1. Reginster J-Y, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 11:83-91
2. Harris ST, Watts NB, Genant HK et al (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized, controlled trial. JAMA 282:1344-1352
3. Chesnut CH III, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241-1249
4. Harris ST, Blumentals WA, Miller PD (2008) Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: Results of a meta-analysis of phase III studies. Curr Med Res Opin 24:237-245
5. Stakkestad JA, Lakatos P, Lorenc R et al (2008) Monthly oral ibandronate is effective and well tolerated after 3 years: The MOBILE long term extension. Clin Rheumatol 27:955-960
6. Lespessailles E (2007) A forgotten challenge when treating osteoporosis: getting patients to take their meds. Jt Bone Spine 74:7-8
7. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E (2003) Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 14:965-968
8. Eastell R, Garnero P, Vrijens B (2003) Influence of patient compliance with risedronate therapy on bone turnover marker and bone mineral density response: The IMPACT study. Calcif Tissue Int 72:408
9. Caro JJ, Ishak KJ, Huybrechts KF et al (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008
10. Simon JA, Lewiecki EM, Smith ME et al (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: A multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886
11. Recker RR, Gallagher R, Amonkar M et al (2004) Medication persistence is better with weekly bisphosphonates, but it remains suboptimal. J Bone Miner Res 19(Suppl 1):SA407
12. Kendler D, Kung AW, Fuleihan Gel H et al (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243-251
13. Emkey R, Koltun W, Beusterien K et al (2005) Patient preference for once monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: The Bonviva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903
14. Hadji P, Minne H, Pfeifer M et al (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Jt Bone Spine 75:303-310
15. Grazio S, Babic-Naglic D, Kehler T et al (2008) Persistence of weekly alendronate: A real-world study in Croatia. Clin Rheumatol 27:651-653
16. Keen R, Jodar E, Iolascon G et al (2006) European women's preference for osteoporosis treatment: Influence of clinical effectiveness and dosing frequency. Curr Med Res Opin 22:2375-2381
17. Weiss TW, Gold D, Silverman S et al (2006) An evaluation of patient preferences for osteoporosis medications and their attributes: Results from the PREFER-US study. Curr Med Res Opin 22:949-960
18. Kastelan D, Korsic M, Vlak T (2008) Ibandronate: Is there an effect on nonvertebral fractures? Clin Rheumatol 27:1313-1315
19. Lydick E, Zimmerman SI, Yawn B et al (1997) Development and validation of a discriminative quality of life questionnaire for osteoporosis (the OPTQoL). J Bone Miner Res 12:456-463
20. The EruoQol Group (1990) EuroQol - a new facility for the measurement of health related quality of life. Health Policy 16:199-208
21. Flood EM, Beusterien KM, Green H et al (2006) Psychometric evaluation of the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4:42
22. Sebaldt RJ, Shane LG, Pham BZ et al (2004) impact on non-compliance and non-persistence with daily bisphosphonates on longer-term effectiveness outcomes in patients with osteoporosis treated in tertiary specialist care. J Bone Miner Res 19(Suppl 1):S445
23. Cotte FE, Cortet B, Lafuma A et al (2008) A model of the public health impact of improved treatment persistence in post-menopausal osteoporosis in France. Jt Bone Spine 75:201-208